在Streptomyces coelicolor中利用聚胺的一种新型合成抑制剂
Sergii Krysenko1, Maria Lopez1,2, Christian Meyners3
1Department of Microbiology and Biotechnology, Interfaculty Institute of Microbiology and Infection Medicine Tübingen (IMIT), University of Tübingen, Auf der Morgenstelle 28, 72076 Tübingen, Germany.
FEMS microbiology letters
|October 5, 2023
概括
研究人员开发了PPU268,这是第一个马-氨基聚胺合成酶 (GlnA2Sc) 抑制剂. 这种化合物阻断了细菌聚胺的利用,为动态细菌感染提供了潜在的新疗法.
科学领域:
- 生物化学 生物化学
- 微生物学 微生物学
- 药物发现 药物发现 药物发现
背景情况:
- 斑马菌使用-胺聚胺合成酶 (GlnA2Sc) 来排毒和代谢多氨酸.
- GlnA2Sc是一种类似谷氨酸合成酶 (GS-like) 的酶,对细菌聚胺管理至关重要.
- 现有的GS抑制剂没有针对GlnA2Sc,突出显示了治疗策略中的差距.
研究的目的:
- 确定和描述第一个 GlnA2Sc.Sc. 抑制剂.
- 探索GlnA2Sc抑制的潜力,用于治疗针对动态细菌病原体的治疗应用.
主要方法:
- 一种新型抑制剂 (PPU268) 的结构衍生,由氨酸硫胺 (MSO) 来制造.
- 描述PPU268的双重机制:MSO的结合和GlnA2Sc基质的特异性.
主要成果:
- PPU268有效地抑制了GlnA2Sc,阻止了细菌聚胺的利用.
- 这种新型的抑制剂可以防止细菌中的聚胺排毒.
- 这种抑制导致不能使用聚氨酸作为碳或源.
结论:
- PPU268是第一个确定的GlnA2Sc. 抑制剂.
- 抑制GlnA2Sc是一种新的策略,可以对抗动态细菌病原体.
- 这种方法可能会为涉及富含聚胺环境的感染带来新的治疗途径.
更多相关视频
09:08From a Natural Product to Its Biosynthetic Gene Cluster: A Demonstration Using Polyketomycin from Streptomyces diastatochromogenes Tü6028
Published on: January 13, 2017
17.2K
12:02An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
Published on: November 2, 2016
12.1K
相关概念视频
Peptidoglycan Synthesis
29
Structure of PeptidoglycanPeptidoglycan is a vital structural component of the bacterial cell wall, providing mechanical strength and shape to the cell. It consists of repeating units of two sugars—N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM)—linked by β-1,4 glycosidic bonds. These sugar chains are cross-linked by short peptide chains, forming a mesh-like polymer that surrounds the bacterial plasma membrane.Cytoplasmic Phase – Precursor SynthesisPeptidoglycan...
29
Enzyme Inhibition
78.5K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.5K
